astrazeneca drug failure
shares drug closed trade failure iressa drug clinical trial
lung cancer drug prolong survival patients disease setback rejection october pill exanta spinners cholesterol drug crestor facing mounting safety concerns blockbuster drugs meant forward failing risks crestor nick turner brokers jefferies
astrazeneca hoped pitch iressa drug rival medicine tarceva iressa proved placebo extending lives trial involving patients tarceva osi pharmaceuticals genentech roche proved successful helping prolong lung cancer patients aztrazeneca appointed executive board john patterson charge drug patterson substantial clinical organisation processes determined improve regulatory performance restore confidence shareholders executive tom mckillop
